AbbVie gains attention as healthcare rotation highlights Skyrizi, Rinvoq, immunology growth, and portfolio strength beyond ...
AbbVie’s $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See ...
On June 22, AbbVie announced that it would acquire Apogee Therapeutics (APGE +0.24%), a biotech company focused on developing medicines for immunological and inflammatory diseases. AbbVie will pay ...
Immunology is AbbVie's primary core competency. While the pharmaceutical company has successfully transitioned patients from Humira to its newer blockbusters, Skyrizi and Rinvoq, the Apogee ...
AbbVie said on Monday it would buy Apogee Therapeutics for $10.9 billion, the company's largest buyout in more than five years, as it seeks to bolster its treatment pipeline for inflammatory ...
AbbVie said today it would buy biotech Apogee Therapeutics for $10.9 billion, in its largest buyout in more than five years to strengthen its next-gen immunology pipeline.
A multi-billion-dollar cash offer and a 60% premium are on the table as AbbVie nears its biggest buyout in seven years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results